Belite Bio reports US$774M in liquidity ahead of tinlarebant FDA date
The company says the FDA will not hold an advisory panel as it prepares for a Feb. 12 decision on its Stargardt disease application.
Adrian Kessler
A US$774 million cash and investment balance backs tinlarebant's regulatory preparations as Belite Bio, Inc NASDAQBLTE reported third-quarter results on Thursday. Its application for Stargardt disease type 1 has a Feb. 12, 2027 U.S. Food and Drug Administration target action date.
The Nov. 12 release listed US$271.3 million in cash and cash equivalents at Sept. 30. A further US$502.7 million was held in U.S. Treasury bills and notes, giving Belite substantial liquid assets ahead of the potential approval decision.
Belite is a San Diego clinical-stage drug developer focused on degenerative retinal diseases, with its pipeline led by tinlarebant. The company is preparing for potential commercialization while pursuing applications outside the United States.
Shares of NASDAQBLTE closed down 0.37 per cent at US$155.94 on Nasdaq at 4:00 p.m. EST on Wednesday. That close preceded Thursday's release and does not show the market's response to the update.
The combined cash and Treasury balance compares with US$772.6 million at Dec. 31, calculated from the release's separate categories. Cash fell while Treasury holdings increased, so the decline in cash alone does not describe the change in those liquid assets.
Research and development expenses rose to US$15.5 million in the third quarter from US$10.3 million a year earlier. Belite attributed the increase principally to manufacturing expenses, consultant fees and sponsorship funding. Those accounting expenses do not measure total cash consumption or establish a launch budget.
The FDA accepted the tinlarebant application with priority review in August, according to Belite. The company also relayed the FDA's position on an advisory panel:
"The Company has been informed by the FDA that it will not convene an advisory committee meeting to discuss the NDA for tinlarebant in STGD1," Belite said in the release.
Belite said the FDA's review remains ongoing. An application accepted for review remains distinct from an approval, and the February target date is the next scheduled U.S. decision point.
Read more: PolyPid reports US$15.5M in liquidity ahead of FDA goal date
The completed Phase 3 DRAGON trial enrolled 104 patients. Participants aged 12 to 20 received tinlarebant or placebo in a two-to-one ratio over 24 months.
Thursday's clinical summary repeated the previously announced 35.7 per cent reduction in retinal-lesion growth versus placebo. The endpoint measured definitely decreased autofluorescence using retinal imaging. Belite described treatment as well tolerated; the summary did not provide a p value or detailed adverse-event counts.
Ocugen Expects Stargardt Data In 2027
The closest development comparison is Ocugen, Inc. NASDAQOCGN, whose Nov. 4 update forecast Stargardt trial data in the second quarter of 2027. Its pivotal OCU410ST study enrolled 63 patients, with a biologics application planned afterward.
Ocugen separately reported US$84.6 million in cash, cash equivalents, restricted cash and short-term investments at Sept. 30, with expected runway into 2028. Its geographic-atrophy program has entered Phase 3, overlapping another indication Belite is pursuing.
Belite's own Phase 3 PHOENIX geographic-atrophy trial has enrolled 530 patients and measures atrophic-lesion growth against placebo. The company expects an interim analysis but supplied no date in Thursday's clinical update.
Japan received Belite's tinlarebant application in September. Applications followed in Singapore, the United Kingdom and Switzerland in October through the Access Consortium pathway, adding regulatory submissions beyond the U.S. review.
Read more: Compass Pathways reports completion of COMP360 psilocybin application
Management's next scheduled update is a Nov. 12 conference call. The next dated regulatory milestone is Feb. 12, 2027, when the FDA is targeted to act on the Stargardt application.
